Efficacy of cyclosporin A in psoriasis: a summary of the United States' experience

• Published in: British journal of dermatology (1951) Vol. 122 Suppl 36; p. 21
• Main Authors: Fradin, M S, Ellis, C N, Voorhees, J J
• Format: Journal Article
• Language: English
• Published: England 01-06-1990
• Subjects: Cyclosporins - administration & dosage; Cyclosporins - therapeutic use; Dose-Response Relationship, Drug; Humans; Psoriasis - drug therapy; Randomized Controlled Trials as Topic; United States; United States
• ISSN: 0007-0963
• DOI: 10.1111/j.1365-2133.1990.tb02878.x

Since its discovery in 1972, cyclosporin A (CyA) has been widely used in the experimental treatment of multiple inflammatory diseases considered to be of immune-mediated aetiology. In dermatology, oral CyA is most effective in the treatment of psoriasis and has been used successfully for plaque-type, pustular and erythrodermic forms of the disease. While dosages ranging from 1 to 14 mg/kg/day have been used, a starting dose of 4 mg/kg/day gives a rapid response with few side-effects. Nephrotoxicity remains the greatest concern in long-term use of the drug. Although intralesional CyA has proven effective in psoriasis, topical preparations have not. It is hoped that future research will provide effective topical formulations of CyA which are efficacious without the risks inherent in systemic administration.